Search

Search Constraints

You searched for: Author/Creator Grossmann, Kenneth F

Search Results

1. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Issue 11 (November 2016)

3. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Issue 4 (April 2015)

4. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Issue 4 (April 2015)

5. Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma. Issue 6 (11th June 2021)

6. Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma. Issue 1 (26th January 2021)

7. Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma. Issue 1 (26th January 2021)

8. Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventative Services Task Force controversy. (March 2017)

9. Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventative Services Task Force controversy. (March 2017)

10. Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy. (March 2017)